source
- Novartis licenses Alteogen’s hyaluronidase enzyme ALT-B4 in new drug delivery partnershipNovartis announced a licensing agreement with South Korean biotech Alteogen to use its hyaluronidase enzyme ALT-B4 for drug delivery applications. The enzyme will be produced using Alteogen’s prop…
- Deaths of two Chinese children receiving CRISPR therapy spark safety debateTwo children in China died after receiving experimental CRISPR-based gene therapies, according to a recent report. The fatalities have unsettled researchers in the United States who are developing…